Athira Pharma Investor Relations Material
Latest events
Status Update
Athira Pharma
Q1 2025
9 May, 2025
Q4 2024
27 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Athira Pharma Inc
Access all reports
Athira Pharma Inc., also known as Athira Pharma, is a late clinical-stage biopharmaceutical company focused on developing small molecules aimed at restoring neuronal health and slowing neurodegeneration. The company's leading product candidate, ATH-1017 (Fosgonimeton), is designed to enhance the activity of the hepatocyte growth factor (HGF) and its receptor, MET. The company is headquartered in Bothell, Washington, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
ATHA
Country
🇺🇸 United States